beclomethasone dipropionate + Aerochamber Plus

Beclomethasone dipropionate (BDP) is a synthetic halogenated glucocorticoid used for the maintenance treatment of asthma. It functions as a prodrug that is rapidly converted by esterase enzymes to its active metabolite, beclomethasone-17-monopropionate (B17MP), which binds with high affinity to the glucocorticoid receptor to exert potent anti-inflammatory effects. In the clinical trial context provided by Chiesi Farmaceutici S.p.A., BDP is administered via a pressurized metered-dose inhaler (pMDI) in conjunction with the Aerochamber Plus (AC Plus) spacer device. The AC Plus is a valved holding chamber designed to optimize the delivery of aerosolized medication to the lower respiratory tract while minimizing oropharyngeal deposition and systemic absorption from the oral cavity. This drug-device combination is particularly critical for pediatric patients (ages 5 to 11) who may struggle with the coordination required for standard pMDI use. Chiesi utilizes this specific configuration in clinical pharmacology studies to evaluate the systemic availability and lung deposition of BDP compared to fixed-dose combinations like CHF 1535.

Brand names

ClenilAerochamber Plus

Other names

BDP + AC Plusbeclomethasone dipropionate + Aerochamber Plus spacer